This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (97) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Baldwin, D. S. Articles by Wittchen, H. -U. Search for Related Content PubMed PubMed Citation Articles by Baldwin, D. S. Articles by Wittchen, H. -U. Social Bookmarking                         What's this?

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

Division of Clinical Neurosciences, University of Southampton, Southampton, UK, dsb1{at}soton.ac.uk

Ian M. Anderson

Department of Psychiatry, University of Manchester, Manchester, UK

David J. Nutt

University of Bristol, Bristol, Psychopharmacology Unit, Bristol, UK

Borwin Bandelow

Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany

A. Bond

Institute of Psychiatry, King’s College, London, UK

Jonathan R. T. Davidson

Department of Psychiatry & Behavioral Science, Duke University Medical Center, Durham, USA

J. A. den Boer

School of Behavioral and Cognitive Neurosciences, University Medical Center Groningen, Groningen, the Netherlands

Naomi A. Fineberg

Department of Psychiatry, University of Hertfordshire, Welwyn Garden City, UK

Martin Knapp

Institute of Psychiatry, King’s College, London, UK

J. Scott

Institute of Psychiatry, King’s College, London, UK

H. -U. Wittchen

Technical University of Dresden and Max Planck Institute of Psychiatry, Munich, Germany

These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.

Key Words: anticonvulsants • antidepressants • antipsychotics • anxiety disorders • anxiolytics • benzodiazepines • cognitive behaviour therapy • evidence-based guidelines • generalized anxiety disorder • obsessive-compulsive disorder • panic disorder • post-traumatic stress disorder • simple phobia • social phobia • SSRI • treatment • venlafaxine

Journal of Psychopharmacology, Vol. 19, No. 6, 567-596 (2005)
DOI: 10.1177/0269881105059253


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Martin-Merino, A. Ruigomez, M.-A. Wallander, S. Johansson, and L. A. Garcia-Rodriguez Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care Fam. Pract., February 1, 2010; 27(1): 9 - 16. [Abstract] [Full Text] [PDF]

				J. Davidson, W. Zhang, K. Connor, J. Ji, K. Jobson, Y. Lecrubier, A. McFarlane, D. Newport, D. Nutt, D. Osser, et al. Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) J Psychopharmacol, January 1, 2010; 24(1): 3 - 26. [Abstract] [PDF]

				T. Rutledge, S. E. Linke, D. S. Krantz, B. D. Johnson, V. Bittner, J.-A. Eastwood, W. Eteiba, C. J. Pepine, V. Vaccarino, J. Francis, et al. Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study Psychosom Med, November 1, 2009; 71(9): 958 - 964. [Abstract] [Full Text] [PDF]

				R. Rupprecht, G. Rammes, D. Eser, T. C. Baghai, C. Schule, C. Nothdurfter, T. Troxler, C. Gentsch, H. O. Kalkman, F. Chaperon, et al. Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects Science, July 24, 2009; 325(5939): 490 - 493. [Abstract] [Full Text] [PDF]

				C. P Alderman, J. T Condon, and A. L Gilbert An Open-Label Study of Mirtazapine as Treatment for Combat-Related PTSD Ann. Pharmacother., July 1, 2009; 43(7): 1220 - 1226. [Abstract] [Full Text] [PDF]

				D. M. Benedek and R. J. Ursano Posttraumatic Stress Disorder: From Phenomenology to Clinical Practice Focus, April 1, 2009; 7(2): 160 - 175. [Abstract] [Full Text] [PDF]

				B. G Bereza, M. Machado, and T. R Einarson Assessing the Reporting and Scientific Quality of Meta-Analyses of Randomized Controlled Trials of Treatments for Anxiety Disorders Ann. Pharmacother., October 1, 2008; 42(10): 1402 - 1409. [Abstract] [Full Text] [PDF]

				J. R. Nash, P. A. Sargent, E. A. Rabiner, S. D. Hood, S. V. Argyropoulos, J. P. Potokar, P. M. Grasby, and D. J. Nutt Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study The British Journal of Psychiatry, September 1, 2008; 193(3): 229 - 234. [Abstract] [Full Text] [PDF]

				C Allgulander, D Nutt, M Detke, J Erickson, M Spann, D Walker, S. Ball, and J. Russell A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder J Psychopharmacol, June 1, 2008; 22(4): 417 - 425. [Abstract] [PDF]

				I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines J Psychopharmacol, June 1, 2008; 22(4): 343 - 396. [Abstract] [PDF]

				D. J. Nutt and M. Sharpe Uncritical positive regard? Issues in the efficacy and safety of psychotherapy J Psychopharmacol, January 1, 2008; 22(1): 3 - 6. [PDF]

				C. Haw and J. Stubbs Benzodiazepines a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital J Psychopharmacol, August 1, 2007; 21(6): 645 - 649. [Abstract] [PDF]

				R. J. Rodgers More haste, considerably less speed J Psychopharmacol, March 1, 2007; 21(2): 141 - 143. [PDF]

				L. M. Drummond, A. Pillay, P. Kolb, and S. Rani Specialised in-patient treatment for severe, chronic, resistant obsessive-compulsive disorder The Psychiatrist, February 1, 2007; 31(2): 49 - 52. [Abstract] [Full Text] [PDF]

				L. M. Koran M.D. Obsessive-Compulsive Disorder: An Update for the Clinician Focus, January 1, 2007; 5(3): 299 - 313. [Full Text] [PDF]

				D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology J Psychopharmacol, January 1, 2007; 21(1): 10 - 41. [Abstract] [PDF]